Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?

about

Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?

Item

http://www.wikidata.org/entity/Q42335930

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Should Low Molecular Weight PS ...... in Ligands for PSMA Targeting?

@en

Should Low Molecular Weight PS ...... in Ligands for PSMA Targeting?

@nl

type

Item

label

Should Low Molecular Weight PS ...... in Ligands for PSMA Targeting?

@en

Should Low Molecular Weight PS ...... in Ligands for PSMA Targeting?

@nl

prefLabel

Should Low Molecular Weight PS ...... in Ligands for PSMA Targeting?

@en

Should Low Molecular Weight PS ...... in Ligands for PSMA Targeting?

@nl

P1476

Should Low Molecular Weight PS ...... in Ligands for PSMA Targeting?

@en

P2093

Steve S Huang

http://www.w3.org/2001/XMLSchema#string

Warren D W Heston

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen

Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase)

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition

The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.

Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker.

Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase).

Expression of the prostate-specific membrane antigen.

DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.

P304

1940-1941

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.7150/THNO.20284

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28638479

http://www.w3.org/2001/XMLSchema#string

P932

5479280

http://www.w3.org/2001/XMLSchema#string